Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Chemogenetics reveals a surprising role for GPR18 signaling in immunometabolic regulation of β cell activity
Xianglin Huang, Bryan L. Roth
Xianglin Huang, Bryan L. Roth
View: Text | PDF
Commentary

Chemogenetics reveals a surprising role for GPR18 signaling in immunometabolic regulation of β cell activity

  • Text
  • PDF
Abstract

Pancreatic islet macrophages are important immunometabolic regulators of β cell function, particularly in obesity-associated type 2 diabetes. Previous studies have established that pancreatic islet macrophages communicate with β cells through either the release of cytokines and growth factors, or direct cell–cell contact. In this issue of the JCI, Singh et al. used chemogenetics to identify a Gq/AMPK pathway that remodels sphingolipid metabolism. This pathway links macrophages to β cells through a CD36-dependent mechanism that reduces insulin secretion. Surprisingly, the orphan GPCR GPR18 was identified as the receptor that engages this pathway. These findings expand our understanding in macrophage–β cell communication and identify GPR18 as a potential therapeutic target for type 2 diabetes.

Authors

Xianglin Huang, Bryan L. Roth

×

Figure 1

The orphan GPCR GPR18 engages a pancreatic macrophage–β cell signaling pathway that reduces insulin secretion.

Options: View larger image (or click on image) Download as PowerPoint
The orphan GPCR GPR18 engages a pancreatic macrophage–β cell signaling p...
(A) Using Gq-coupled DREADD, Singh et al. (15) identified a Gq/AMPK/sphingolipid signaling pathway in macrophage–β cell communications. Selective activation of Gq-DREADD led to increased activation of AMPK, which remodeled the sphingolipid recycling pathways and led to release of sphingolipids and their derivatives from macrophages. CD36 on β cells facilitated the uptake of these lipids into β cells, leading to increased phosphorylation of PKCζ as well as reduced phosphorylation of AKT and GSK3β. The activation of GSK3β resulted in reduced insulin secretion. Singh et al. then identified GPR18 as an endogenous GPCR mediating this Gq-dependent pathway. (B) These findings position GPR18 as a potential target in T2D, alongside other GPCRs that have been implicated in insulin-regulating macrophage–β cell interactions.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts